METTL3 drives malignant progression in TP53-mutant prostate cancer.
1/5 보강
[BACKGROUND] Prostate cancer patients harboring mutations exhibit a more aggressive and chemo-resistant phenotype.
APA
Pu Y, Ye D, et al. (2025). METTL3 drives malignant progression in TP53-mutant prostate cancer.. Molecular biology reports, 53(1), 66. https://doi.org/10.1007/s11033-025-11160-4
MLA
Pu Y, et al.. "METTL3 drives malignant progression in TP53-mutant prostate cancer.." Molecular biology reports, vol. 53, no. 1, 2025, pp. 66.
PMID
41217561 ↗
Abstract 한글 요약
[BACKGROUND] Prostate cancer patients harboring mutations exhibit a more aggressive and chemo-resistant phenotype. Unfortunately, attempts to identify the vulnerabilities that could be exploited to overcome these aggressive malignancies have made only minimal progress in recent years. Consequently, there is an immediate requirement to investigate novel therapeutic strategies for this subclass. METTL3 complex, knowing to govern m6A dynamic alteration, has been suggested to be a critical therapeutic target across human cancer. However, the role of METTL3 in prostate cancer harboring mutations is totally unknown.
[MATERIALS AND METHODS] Bioinformatic analysis was employed to assess the transcriptome signature between and prostate cancer and the expression of METTL3 complex in and prostate cancer. Colony formation and growth curve analyses were employed to assess the role of METTL3 in prostate cancer. Furthermore, the bioinformatic analyses were utilized for uncovering the underlying mechanism of how METTL3 maintained the malignancy phenotype of prostate cancer.
[RESULTS] as one of the most frequently mutated genes in prostate cancer. Transcriptome analysis revealed that mutation significantly downregulated genes associated with prohibiting proliferation. Moreover, the core catalytic subunit, METTL3, was found to be aberrantly upregulated in TP53 mutated prostate cancer compared to that in normal and prostate tissues. Notably, pharmaceutically blockade of METTL3 drastically inhibited mutated prostate cancer cells growth. Bioinformatic analysis suggested that METTL3 inhibition maintained mutated prostate cancer malignancies via activating MAPK signaling.
[CONCLUSIONS] METTL3 serves as a novel targetable vulnerability for prostate cancer. Targeting METTL3 prohibits the mutated prostate cancer growth by inactivating MAPK signaling.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s11033-025-11160-4.
[MATERIALS AND METHODS] Bioinformatic analysis was employed to assess the transcriptome signature between and prostate cancer and the expression of METTL3 complex in and prostate cancer. Colony formation and growth curve analyses were employed to assess the role of METTL3 in prostate cancer. Furthermore, the bioinformatic analyses were utilized for uncovering the underlying mechanism of how METTL3 maintained the malignancy phenotype of prostate cancer.
[RESULTS] as one of the most frequently mutated genes in prostate cancer. Transcriptome analysis revealed that mutation significantly downregulated genes associated with prohibiting proliferation. Moreover, the core catalytic subunit, METTL3, was found to be aberrantly upregulated in TP53 mutated prostate cancer compared to that in normal and prostate tissues. Notably, pharmaceutically blockade of METTL3 drastically inhibited mutated prostate cancer cells growth. Bioinformatic analysis suggested that METTL3 inhibition maintained mutated prostate cancer malignancies via activating MAPK signaling.
[CONCLUSIONS] METTL3 serves as a novel targetable vulnerability for prostate cancer. Targeting METTL3 prohibits the mutated prostate cancer growth by inactivating MAPK signaling.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s11033-025-11160-4.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- pH-Sensitive Long-Circulating Nanoliposomes with CU1 for Effective Against Lung Cancer.
- Endothelial TBK1 Deficiency Inhibits Endothelial-to-Mesenchymal Transition and Atherogenesis Through Suppressing PAK1/ERK1/2 Signaling.
- Concomitant laryngeal squamous cell carcinoma and prostate cancer on F-FDG PET/CT and F-PSMA-1007 PET/CT.
- Retraction notice to "KDM5B-mediated microRNA-448 up-regulation restrains papillary thyroid cancer cell progression and slows down tumor growth via TGIF1 repression" [Life Sci. 250 (2020) 117519].
- The role of postmastectomy radiation therapy in patients with immediate prosthetic breast reconstruction: A meta-analysis.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- CD47 promotes mitogen-activated protein kinase and epithelial-to-mesenchymal transition molecular programs to drive prometastatic phenotypes in non-small cell lung cancer.
- Integrated Transcriptomics Reveals a SHEV ORF3-Mediated circRNA Network That Disrupts Riboflavin Metabolism and Activates the ko05212 Pathway.
- Circulating cell-free DNA as an integrative biomarker in breast cancer: correlation with molecular subtypes, mutation status, and treatment response.
- Lipid deposition promotes YTHDF3-mediated m6A modification of PPARα to facilitate liver metastasis of colorectal cancer.
- Mechanistic overview and suggested strategies to overcome BCL-2 inhibitor resistance in mutated acute myeloid leukemia.
- RNA‑binding proteins as epithelial transcriptome orchestrators in gastric cancer: Immune‑metabolic crosstalk and therapeutic vulnerability (Review).